Literature DB >> 17491070

Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.

J D Webster1, V Yuzbasiyan-Gurkan, R A Miller, J B Kaneene, M Kiupel.   

Abstract

Canine cutaneous mast cell tumor (MCT) is a common neoplastic disease in dogs. Due to the prevalence of canine MCTs and the variable biologic behavior of this disease, accurate prognostication and a thorough understanding of MCT biology are critical for the treatment of this disease. The goals of this study were to evaluate and compare the utility of the proliferation markers Ki67, proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing region (AgNOR) as independent prognostic markers for canine MCTs and to evaluate the use of these markers in combination, as each marker assesses different aspects of cellular proliferation. An additional goal of this study was to evaluate the associations between cellular proliferation and c-KIT mutations and between cellular proliferation and aberrant KIT protein localization in canine MCTs. Fifty-six MCTs treated with surgical excision alone were included in this study. Each MCT was evaluated for Ki67 expression, PCNA expression, and KIT protein localization using immunohistochemistry; for AgNOR counts using histochemical staining; and for the presence of internal tandem duplication c-KIT mutations using polymerase chain reaction amplification. In this study, increased Ki67 and AgNOR counts were both associated with significantly decreased survival. On the basis of these results, we recommend that the evaluation of cellular proliferation, including evaluations of both Ki67 expression and AgNORs, should be routinely used in the prognostication of canine MCTs. Additionally, the results of this study show that MCTs with aberrant KIT protein localization or internal tandem duplication c-KIT mutations are associated with increased cellular proliferation, further suggesting a role for c-KIT in the progression of canine MCTs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17491070     DOI: 10.1354/vp.44-3-298

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  31 in total

1.  Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Seyed Rashid Touni; Hamed Zamankhan Malayeri; Aram Mokarizadeh; Mehdi Pourzaer; Maryam Pourzaer; Shahram Zehtabian; Sheida Mohajer; Sharareh Ahmadi
Journal:  Tumour Biol       Date:  2014-10-15

2.  Feline progressive histiocytosis: a retrospective investigation of 26 cases and preliminary study of Ki67 as a prognostic marker.

Authors:  Margaux Coste; Daniela Prata; Vittoria Castiglioni; Lucia Minoli; Claire-Lise Etienne-Raffestin; Lilia Boulouha; Stéphanie Moreau; Marie Lagadic
Journal:  J Vet Diagn Invest       Date:  2019-10-25       Impact factor: 1.279

3.  Prognostic significance of Ki67 and its correlation with mitotic index in dogs with diffuse large B-cell lymphoma treated with 19-week CHOP-based protocol.

Authors:  Oscar R Sierra Matiz; Juliana Santilli; Leticia A Anai; Maria C L Da Silva; Felipe A Sueiro; Júlio L Sequeira; Larissa F Magalhães; Geórgia M Magalhães; Mirela Tinucci Costa; Sabryna G Calazans
Journal:  J Vet Diagn Invest       Date:  2017-12-01       Impact factor: 1.279

4.  KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Authors:  Cheryl A London; Heather L Gardner; Sarah Rippy; Gerald Post; Krista La Perle; Linda Crew; Lori Lopresti-Morrow; Andrew J Garton; Gerald McMahon; Theresa M LaVallee; Richard Gedrich
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

5.  Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

Authors:  K S Carlsten; C A London; S Haney; R Burnett; A C Avery; D H Thamm
Journal:  J Vet Intern Med       Date:  2011-12-19       Impact factor: 3.333

6.  Digital pathology and image analysis augment biospecimen annotation and biobank quality assurance harmonization.

Authors:  Bih-Rong Wei; R Mark Simpson
Journal:  Clin Biochem       Date:  2013-12-18       Impact factor: 3.281

7.  The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

Authors:  K Shiomitsu; E Sajo; C Rubin; I Sehgal
Journal:  Vet Comp Oncol       Date:  2013-06-13       Impact factor: 2.613

8.  The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Authors:  Alexandra Keller; Bettina Wingelhofer; Barbara Peter; Karin Bauer; Daniela Berger; Susanne Gamperl; Martin Reifinger; Sabine Cerny-Reiterer; Richard Moriggl; Michael Willmann; Peter Valent; Emir Hadzijusufovic
Journal:  Vet Comp Oncol       Date:  2017-04-11       Impact factor: 2.613

9.  Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes.

Authors:  Robert Klopfleisch; Anja Meyer; Patricia Schlieben; Angelika Bondzio; Chris Weise; Dido Lenze; Michael Hummel; Ralf Einspanier; Achim D Gruber
Journal:  BMC Vet Res       Date:  2012-06-29       Impact factor: 2.741

10.  Ki-67 labeling in canine perianal glands neoplasms: a novel approach for immunohistological diagnostic and prognostic.

Authors:  Rodrigo Storti Pereira; Augusto Schweigert; Guilherme Dias de Melo; Fernando Vissani Fernandes; Felipe Augusto Ruiz Sueiro; Gisele Fabrino Machado
Journal:  BMC Vet Res       Date:  2013-04-20       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.